SAA Immunosuppressive treatment

1
Autologous Transplantation in Plasma Cell
Leukaemia Survival
Median survival MM 54.9 PCL 20.9 p 0.000
2
NUMBER OF MINI TRANSPLANTS IN CLWP-REGISTRY
3
Myeloma - RIC Allografts Patient Characteristics
256 patients with myeloma
n ()
Median Age at RICT
52 (32-66)
MF ratio
1.61
Disease duration
1.7
yrs (0.3-11)
gt 1
yr to transplant
182 (71)
171 (79)
Recipient CMV IgG
ve
Status at transplant CR
17 (8)
121 (54)
PR
Stable
21 (9.4)
Progression
65 (29)
st
1
Remission
52 (23)
4
Myeloma Reduced Intensity Conditioned Allografts
Overall and PFS
n254
2yr OS 50
2yr PFS 38
5
CMLReduced Intensity Conditioned Allografts
Overall and PFS
n223
2yr OS 54
2yr PFS 38
6
Survival after Autologous SCT for CML Effect of
Cytogenetic response at 1-2 years post SCT in
patients refractory to IFN pre-SCT
1
.
0
Complete or Major Response (n17)
.
8
Probability of Survival
.
6
.
4
.
2
Minor or Null Response (n38)
p0.01
1
0
0
8
0
6
0
4
0
2
0
0
Months
March 2003
7
HLA-identical sibling Transplants in MDS/sAL
Survival Cox analysis on Transplant Year
1,00
1997
2000
,80
2001
1998
1999
,60
1995
,40
1994
,20
1996
0,00
60
48
36
24
12
0
Average HR 0.96 over 1994-2001 MONTHS
8
Matched Unrelated Transplants in MDS/sAL
Survival Cox analysis on Transplant Year
1,00
2000
1999
,80
2001
1998
,60
1995
1997
,40
,20
1994
1996
0,00
60
48
36
24
12
0
Average HR 0.91 over 1994-2001 MONTHS
9
HLA-id. sibling Transplants in MDS/sAL gt 1995
RFS Stage at Transplant
1,00
,80
,60
early (N426)
,40
intermediate (N155)
,20
plt0.01
advanced (N292)
0,00
60
48
36
24
12
0
MONTHS
10
HLA-id Transplants in Early Stage in MDS/sAL gt
1995
RFS Age classes
1,00
,80
lt 20 yrs (N45)
,60
20-39 yrs (N116)
,40
40-49 yrs (N137)
gt 60 yrs (N26)
50-59 yrs (N100)
,20
p0.14
0,00
60
48
36
24
12
0
MONTHS
11
Autologous Transplants in MDS/sAL gt 1991
EFS Source of Stem Cell
1,00
,80
,60
,40
BM (N219)
,20
p0.39
PB (N342)
0,00
60
48
36
24
12
0
MONTHS